Prostate Cancer Recurrence Linked to High Cholesterol

Share this content:
Findings suggest that normalization of blood fats may reduce risk of prostate cancer.
Findings suggest that normalization of blood fats may reduce risk of prostate cancer.

After surgery for prostate cancer, elevated levels of cholesterol and triglycerides may be linked with greater risk of the cancer's return, new research suggests. The findings were published in Cancer Epidemiology, Biomarkers & Prevention.

Among the 843 men in the study, 325 had abnormal cholesterol levels, 263 had abnormal triglyceride levels, and 293 had a recurrence of prostate cancer.

Men who had triglyceride levels of 150 mg/dL or higher had a 35 percent increased risk of cancer recurrence, compared with men with normal triglyceride levels, the researchers found. Moreover, every 10 mg/dL increase in cholesterol above 200 mg/dL was linked with a 9 percent increase in risk for the return of prostate cancer.

RELATED: Higher Lipoprotein Cholesterol May Protect Against Cancer

"These findings suggest that normalization, or even partial normalization, of blood fats among men with high cholesterol and triglycerides may reduce the risk of prostate cancer recurrence," lead researcher Emma Allott, Ph.D., of the Duke University School of Medicine in Durham, N.C., told HealthDay.


  1. Allott, Emma H., et al. "Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database." Cancer Epidemiology, Biomarkers & Prevention. doi: 10.1158/1055-9965.EPI-14-0458. October 10, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs